Search
for
Sort by
Research 61–90 of 77
- Protein degradation: expanding the toolbox to restrain cancer drug resistance
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- Treatment Strategies for Cutaneous and Oral Mucosal Side Effects of Oncological Treatment in Breast Cancer: A Comprehensive Review
- Amphiregulin in Fibrotic Diseases and Cancer
- Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female
- Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes
- Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review
- Amphiregulin in Fibrotic Diseases and Cancer
- Drug-induced hair pigmentation: Clinical perspectives and updates
- Medical Dermatology
- Inhaled Medicines for Targeting Non-Small Cell Lung Cancer
- Imatinib-induced classical lichen planopilaris in blaschko-linear distribution leading to cicatricial alopecia
- 3D organotypic skin models recapitulate autoantibody-driven pemphigus pathomechanisms and targeted therapeutic response
- Natural Compounds Targeting MAPK, PI3K/Akt, and JAK/STAT Signaling in Papillary Thyroid Cancer
- Dacomitinib-Induced Paronychia Associated With PRIDE Syndrome in a Patient With Non-Small Cell Lung Cancer
- Erlotinib-induced trichomegaly of eyelashes in lung cancer treatment: Epidermal growth factor receptor inhibitor side effect
- ST14 interacts with TMEFF1 and is a predictor of poor prognosis in ovarian cancer
- Dermatologic adverse events in EGFR-TKIs: A real-world analysis.
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
- The PDGF/PDGFR pathway as a drug target
- Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia
- Erlotinib-Associated Alopecia in a Lung Cancer Patient
- Tyrosine kinase Inhibitors in Dermatology: A Systemic Review
- Spotlight commentary: Navigating the cutaneous side effects of chemotherapy
- Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib
- Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities